BioSpace News Archive

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter of 2022 and highlighted recent achievements.

Immunocore Holdings plc (Nasdaq: IMCR) has today presented new translational data on KIMMTRAK (tebentafusp-tebn) in patients with metastatic uveal melanoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, presented preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, today at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

ImCheck Therapeutics presented today the first patient data from EVICTION-2, a Phase I/II clinical trial evaluating the combination of ImCheck’s lead program, ICT01, a γ9δ2 T cell-activating monoclonal antibody targeting BTN3A, combined with low-dose (LD) IL-2, to selectively expand the number of γ9δ2 T cells in relapsed/refractory patients with solid tumors.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeutics (“Emerald”). Both companies’ shareholders voted in favor of the transaction and the Supreme Court of British Columbia approved the transaction.

Bruin Biometrics’ pioneering Provizio® SEM Scanner Sensor for pressure injury risk detection has been made available free at the point of care to all community patients in England, Wales, Scotland, and Northern Ireland; a covered population exceeding 1 million at-home patients.

The Nutraceuticals Market was valued at US$ 498.86 billion in 2021 and is anticipated to reach US$ 1025 billion by 2030, growing at an estimated CAGR of 8.33% from 2022 to 2030.

The global scaffold technology market was predicted to be USD 1.14 billion in 2021 and is anticipated to reach over USD 2.63 billion by 2030, growing at a CAGR of 9.68% from 2022 to 2030.

Avstera Therapeutics Corp has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avstera’s AVS100 compound, which is a highly specific HDAC6 inhibitor, for the treatment of stage IIB through IV melanoma.

As per Precedence Research, the global cell lysis and disruption market size is expanding around US$ 7.1 billion by 2030 and growing at a CAGR of 6.7% from 2021 to 2030.